Slightly more than one year after reporting 12-week data from its Phase IIb VOYAGE trial showing that VK-2809 can significantly reduce liver fat content in metabolic-associated steatohepatitis (MASH), Viking Therapeutics, Inc. bolstered those findings on 4 June with 52-week, histologic data from the study that also demonstrated a statistically significant benefit on reducing fibrosis.
Key Takeaways
-
Viking reports 52-week biopsy data for VK2809 in MASH, bolstering the case made with 12-week data in 2023 for MASH resolution with the drug.
The data position the San Diego-based firm to seek an end-of-Phase II meeting with the US Food and Drug Administration...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?